<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02195453</url>
  </required_header>
  <id_info>
    <org_study_id>yl-yxb08-lcsyfa-201302</org_study_id>
    <nct_id>NCT02195453</nct_id>
  </id_info>
  <brief_title>Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shandong Cancer Hospital and Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe quality of life and treatment side effects in
      patients with advanced non small cell lung cancer (NSCLC) receive chemotherapy and
      Yangzhengxiaoji capsule.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional Assessment of Cancer Therapy-Lung scale</measure>
    <time_frame>84day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung Cancer Symptom Scale</measure>
    <time_frame>84day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-cancer drugs common grading evaluation of adverse reaction</measure>
    <time_frame>84day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completion of chemotherapy</measure>
    <time_frame>84 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>84day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>84 day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">520</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Yangzhengxiaoji Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine or Pemetrexed
Cisplatin
Yangzhengxiaoji Capsule four granules t.i.d po</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gemcitabine or Pemetrexed
Cisplatin
Placebo Capsule four granules t.i.d po</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yangzhengxiaoji Capsule</intervention_name>
    <description>Gemcitabine 1000mg/m² or Pemetrexed 500mg/m² IV drip on D1 and D8,21 days for a cycle.
Cisplatin 75mg/m² IV drip for one day or two-three days total injection,21 days for a cycle.
Yangzhengxiaoji Capsule four granules t.i.d po.</description>
    <arm_group_label>Yangzhengxiaoji Capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Capsule</intervention_name>
    <description>Gemcitabine 1000mg/m² or Pemetrexed 500mg/m²IV drip on D1 and D8,21 days for a cycle.
Cisplatin 75mg/m² IV drip for one day or two-three days total injection, 21 days for a cycle.
Placebo Capsule four granules t.i.d po.</description>
    <arm_group_label>Placebo Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Histology and/or cytology confirmed stage Ⅳ NSCLC patients;

          2. With at least one measurable solid tumor (RECIST standard version 1.1): tumor &gt;=10 mm
             in diameter on CT or MRI images, or lymph node &gt;=15 mm in diameter on CT or MRI
             images;

          3. Eastern Cooperative Oncology Group(ECOG) score 0-1, expectant survival &gt; 3 months;

          4. Age: 18-70 years;

          5. Normal organ function:

             Bone marrow: neutrophils (ANC) count&gt;=1.5×10^9/L, Platelets count&gt;=100×10^9/L,
             hemoglobin&gt;=90g/L；Renal function, serum creatinine&lt;=1.5 mg/dl, and/or creatinine
             clearance or&gt;=60 ml/min; Liver function: total serum bilirubin levels &lt;= 1.5 times the
             upper limit of normal (ULN), serum aspartate aminotransferase (AST) or serum alanine
             aminotransferase (ALT)&lt;=2.5 times the ULN, if abnormal liver function caused by the
             underlying malignancy, the AST and ALT &gt;=5 times ULN;

          6. For patients with brain metastases, bone metastases or pleural effusion, systemic
             chemotherapy is proposed after the effective local treatment to control symptoms;

          7. Informed consent.

        Exclusion criteria:

          1. Clinically significant hepatic dysfunction: AST or ALT &gt; 2.5 times the ULN, total
             serum bilirubin levels &gt; 1.5 times the ULN; clinically significant renal
             insufficiency: serum creatinine &gt; 1.5 times the ULN;

          2. Severe heart disease: New York Heart Association class Ⅲ-IV class of heart failure,
             unstable angina, myocardial infarction, coronary revascularization six months before
             randomization;

          3. Spleen resection or combined with other severe hematopoietic system diseases;

          4. Uncontrolled diabetes, hypertension (above 180/120mmHg), infection or severe
             gastrointestinal ulcers;

          5. History or present with other cancer, except for non melanoma skin cancer, cervical
             cancer in situ and other cured cancer for at least 5 years;

          6. Mental illness, without legal capacity or limited capacity;

          7. Pregnancy, lactation or patients with pregnancy plan;

          8. Participated in other clinical trail in the past 1 months or participating in other
             trail now;

          9. Other unsuitable condition decided by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinming Yu, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Shandong Cancer Hospital and Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jie Wang, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Biejing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ligang Xing, M.D.</last_name>
    <phone>18053100188</phone>
    <email>xinglg@gmail.com</email>
  </overall_contact>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2014</study_first_submitted>
  <study_first_submitted_qc>July 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2014</study_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Cancer Hospital and Institute</investigator_affiliation>
    <investigator_full_name>Jinming Yu</investigator_full_name>
    <investigator_title>Shandong Cancer Hospital and Institute</investigator_title>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>FACT-L scale</keyword>
  <keyword>Yangzhengxiaoji</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

